NCT04201834

Risperidone for the Treatment of Huntington's Disease Involuntary Movements

Risperidone for the Treatment of Huntington's Disease Chorea

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and benefit of risperidone for the treatment of chorea (involuntary movements) in Huntington's disease. Risperidone is commonly used in clinical practice to treat chorea, however, it has not been approved by the Food and Drug Administration (FDA) to treat chorea. This study will examine 1) whether the investigators see MRI changes with risperidone treatment and 2) whether sensors applied to the participants body can measure chorea and detect changes in chorea.

Conditions

• Huntington Disease
• Chorea

Interventions

Type	Name	Description
DRUG	Risperidone	capsule or tablet, 0.5 mg
DEVICE	BioStamp nPoint device	MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.

Timeline

• Start date: 2020-08-13
• Primary completion: 2023-12-30
• Completion: 2023-12-30
• First posted: 2019-12-17
• Last updated: 2025-03-21
• Results posted: 2025-03-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study